论文部分内容阅读
阿比特龙(商品名:ZYTIGA)是作用于17α-羟化酶/C17,20裂解酶的一种雄激素生物合成抑制剂,主要用于治疗转移性去势抵抗性前列腺癌(mCRPC)。近年来,阿比特龙的药动学、药效学及其临床治疗进展期mCRPC的有效性得到进一步阐明,阿比特龙潜在不良反应和新的临床应用也陆续报道。本文对阿比特龙的药理作用及其临床研究进展作一综述。
Abiraterone (trade name: ZYTIGA) is an androgen biosynthesis inhibitor that acts on 17α-hydroxylase / C17,20 lyase and is mainly used to treat metastatic castration-resistant prostate cancer (mCRPC). In recent years, the pharmacokinetics and pharmacodynamics of abiraterone and the clinical efficacy of mCRPC have been further elucidated. The potential adverse effects of abiraterone and new clinical applications are also reported. This article reviews the pharmacological effects of abiraterone and its clinical progress.